Modifications, such as the overexpression of miRNAs, in the post-transcriptional control of a gene can result in cancer.
- Explain how post-transcriptional control can result in cancer
- Specific cancers have altered expression of miRNAs; changes in the miRNA population of particular cancers varies depending on the type of cancer.
- Having too many miRNAs can dramatically decrease the RNA population leading to a decrease in protein expression.
- Studies have found that some miRNAs are specifically expressed only in cancer cells.
- microRNA: a single-stranded, non-coding form of RNA, having only about 20-30 nucleotides, that has a number of functions including the regulation of gene expression
- exosome: a vesicle responsible for the selective removal of plasma membrane proteins
Cancer and Post-transcriptional Control
Post-transcriptional regulation is the control of gene expression at the RNA level; therefore, between the transcription and the translation of the gene. After being produced, the stability and distribution of the different transcripts is regulated (post-transcriptional regulation) by means of RNA-binding proteins (RBP) that control the various steps and rates of the transcripts: events such as alternative splicing, nuclear degradation (exosome), processing, nuclear export (three alternative pathways), sequestration in DCP2-bodies for storage or degradation, and, ultimately, translation.
Changes in the post-transcriptional control of a gene can result in cancer. Recently, several groups of researchers have shown that specific cancers have altered expression of microRNAs (miRNAs). miRNAs bind to the 3′ UTR or 5′ UTR of RNA molecules to degrade them. Overexpression of these miRNAs could be detrimental to normal cellular activity. An increase in many miRNAs could dramatically decrease the RNA population leading to a decrease in protein expression. Several studies have demonstrated a change in the miRNA population in specific cancer types. It appears that the subset of miRNAs expressed in breast cancer cells is quite different from the subset expressed in lung cancer cells or even from normal breast cells. This suggests that alterations in miRNA activity can contribute to the growth of breast cancer cells. These types of studies also suggest that if some miRNAs are specifically expressed only in cancer cells, they could be potential drug targets. It would, therefore, be conceivable that new drugs that turn off miRNA expression in cancer could be an effective method to treat cancer.